期刊文献+

生长抑素受体显像剂^(99)Tc^m-HTOC的制备 被引量:2

Preparation of SSTR-positive tumor targeting tracer ^(99)Tc^m-HTOC
下载PDF
导出
摘要 目的 研制99Tcm 标记的生长抑素受体 (SSTR)阳性肿瘤显像剂99Tcm 6 肼基烟酰基 [Tyr3] octreotide (HTOC)。方法 通过四步化学反应合成 ,HPLC纯化 ,得到HTOC ;用乙二胺 N ,N′ 二乙酸 (EDDA)作为配体进行99Tcm 标记 ,测定标记率与标记物稳定性。结果 所合成HTOC质谱的分子离子峰与HTOC相对分子质量一致 ,99Tcm HTOC标记率 >95 % ,标记后 6h放化纯仍 >95 %。结论该法研制的99Tcm HTOC标记率高 ,体外稳定性好。 Objective To explore the 99 Tc m-HYNIC-[Tyr 3]-octreotide (HTOC) which is 99 Tc m labeled somatostatin receptors (SSTR) imaging agent. Methods HTOC was obtained by four steps of chemical reaction,purified by HPLC and labeled with 99 Tc m using ethylenediamine diacetic acid (EDDA) as coligand;the labeling yield,radiochemical purity and stability in vitro were determined by instant thin layer chromatography-sillica gel (ITLC-SG) and HPLC. Results The structure of HTOC was confirmed by matrix assistant laser desorption ionization-time of flight-mass spectroscopy (MALDI-TOF-MS). The labeling yield was more than 95% and remained high in vitro by 6 h after labeling. Conclusion The labeling yield of 99 Tc m-HTOC prepared with the methodology reported here is high and the stability of 99 Tc m-HTOC in vitro and in vivo is good.
机构地区 中国医学科学院
出处 《中华核医学杂志》 CAS CSCD 北大核心 2004年第4期241-242,共2页 Chinese Journal of Nuclear Medicine
基金 首都医学发展科研基金资助项目 (2 0 0 2 0 2 1 1 )
关键词 ^99TC^M标记 标记率 生长抑素受体显像 肿瘤显像 阳性 标记物 HPLC 合成 乙二胺 制备 Receptors,somatostatin Radionuclide imaging Chemical synthesis Isotope labeling HTOC
  • 相关文献

参考文献5

  • 1Clemens D, Stephen JM. Preparation, 99 Tcm labelling, and in vitro characterization of HYNIC and N3S modifide RC-160 and [Tyr3]-octreotide. Bioconjug Chem, 1999, 10: 431-438.
  • 2Clemens D, Laura MA, Jane KS, et al. 99 Tcm-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111 In-octreotide. J Nucl Med, 2000, 41: 1114-1119.
  • 3Michael JA, Malik J, Tenkate CI, et al. 99 Tcm-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med, 1990, 31: 2022-2028.
  • 4王正英,杜延荣,陈方,欧阳萌,李方.肿瘤显像剂^(99)Tc^m-HYNIC-TOC荷胰腺癌裸鼠的显像[J].同位素,2002,15(4):200-203. 被引量:3
  • 5Clemens D, Stephen JM,Witold C, et al. 99 Tcm-EDDA/HYNIC-TOC: a new, 99 Tcm labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111 In labelled octreotide derivatives. Eur J Nucl Med, 2000, 27: 1318-1325.

二级参考文献3

  • 1Krenning EP, Bakker WH,Kooij PPM, et al. Somatostatin Receptor Sintigraphy With 111In-DTPA-D-Phe1-octreotide in Man: Metablish, Dosimetry and Comparison With I-123-Tyr3-octreotide[J].J Nucl Med, 1992,33:652~658.
  • 2Krenning EP, Kwekkeboom DW,Bakker WH,et al.Somatostatin Receptor Sintigraphy With[111In-DTPA-D-Phe]-and [123I-Tyr3]-octreotide:the Rotterdam Experience With More Than 1000 Patients[J]. Eur J Nucl Med, 1993,20(7):716~731.
  • 3Clemens Decristoforo, Mather SJ. Technetium-99m Somatostatin Analogues: Effect of Labelling Methods and Peptide Sequence[J]. Eur J Nucl Med, 1999, 26(8): 869~876.

共引文献2

同被引文献17

  • 1Reubi JC.Peptide receptors as molecular targets for cancer diagnosis and therapy.Endocr Rev,2003,24:389-427.
  • 2Reubi JC.Badiopeptide targeting for tumor therapy:peptide receptor distribution//Chinol M,Paganelli G.Radionuclide peptide cancer therapy.New York:Taylor Francis Group,2006:31-38.
  • 3Weiner RE,Thakur ML.Developments of radiolabeled peptides//Chinol M,Paganelli G.Radionuclide peptide cancer therapy.New York:Taylor Francis Group,2006:41-48.
  • 4Kwekkeboom DJ,Mueller-Brand J,Paganelli G,et al.Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.J Nucl Med,2005,46:62S-66S.
  • 5Kwekkeboom DJ,Teunissen JM,Kam BL,et al.Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.Hematol Oncol Clin North Am.2007,21:561-573.
  • 6Kaltsas GA,Papadogias D,Makras P,et al.Treatment of advanced neuroendocrine tumors with radiolabelled somatostatin analogues.Endocr Relat Cancer,2005,12:683-699.
  • 7Waldherr C,Pless M,Maecke HR,et al.Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC.J Nucl Med,2002,43:610-616.
  • 8van Essen M,Krenning EP,De Jong M,et al.Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.Acta Oncologica,2007,46:723-734.
  • 9Herder WW,Hofland LJ,Lely AJ,et al.Somatostatin receptors in gastroenteropancreatie neuroendocrine tumors[J].Endocrine-Related Cancer,2003,10:451.
  • 10Kaltsas GA,Papadogias D,Makras P,et al.Treatment of advanced neuroendocrine tumors with radiolabelled somatostatin analogues[J].Endocrine-Related Cancer,2005,12:683.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部